Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey A Lieberman

Showing results (1-10 of 366) with videos related to

Pageof 37
Sort By:
CNS Drugs|March 16, 2004
Dopamine partial agonists: a new class of antipsychoticJeffrey A Lieberman
The American Journal of Psychiatry|October 3, 2013
Response to the presidential addressJeffrey A Lieberman
The New England Journal of Medicine|April 14, 2021
Back to the Future - The Therapeutic Potential of Psychedelic DrugsJeffrey A Lieberman
Archives of General Psychiatry|October 4, 2006
Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE)Jeffrey A Lieberman
The American Journal of Psychiatry|September 2, 2015
Response to KornfeldJeffrey A Lieberman
Psychiatric Services (Washington, D.C.)|July 28, 2006
What the CATIE study means for clinical practiceJeffrey A Lieberman
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|June 2, 2018
Disease modifying effects of antipsychotic drugs in schizophrenia: a clinical and neurobiological perspectiveJeffrey A Lieberman
The Journal of Clinical Psychiatry|March 6, 2007
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trialsJeffrey A Lieberman
CNS Spectrums|November 21, 2007
An interview with Jeffrey A. Lieberman: Tardive Dyskinesia. [interview by Sussman Norman]Jeffrey A Lieberman
The American Journal of Psychiatry|July 2, 2014
Our future is nowJeffrey A Lieberman
Pageof 37

Showing results (1-10 of 366) with videos related to

Sort By:
Pageof 37
CNS Drugs|March 16, 2004
Dopamine partial agonists: a new class of antipsychoticJeffrey A Lieberman
The American Journal of Psychiatry|October 3, 2013
Response to the presidential addressJeffrey A Lieberman
The New England Journal of Medicine|April 14, 2021
Back to the Future - The Therapeutic Potential of Psychedelic DrugsJeffrey A Lieberman
Archives of General Psychiatry|October 4, 2006
Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE)Jeffrey A Lieberman
The American Journal of Psychiatry|September 2, 2015
Response to KornfeldJeffrey A Lieberman
Psychiatric Services (Washington, D.C.)|July 28, 2006
What the CATIE study means for clinical practiceJeffrey A Lieberman
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|June 2, 2018
Disease modifying effects of antipsychotic drugs in schizophrenia: a clinical and neurobiological perspectiveJeffrey A Lieberman
The Journal of Clinical Psychiatry|March 6, 2007
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trialsJeffrey A Lieberman
CNS Spectrums|November 21, 2007
An interview with Jeffrey A. Lieberman: Tardive Dyskinesia. [interview by Sussman Norman]Jeffrey A Lieberman
The American Journal of Psychiatry|July 2, 2014
Our future is nowJeffrey A Lieberman
Pageof 37